Overview

Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
To determine the safety and efficacy of the combination of bevacizumab and everolimus (RAD001) for the treatment of metastatic renal cell cancer
Phase:
Phase 2
Details
Lead Sponsor:
Sandy Srinivas
Collaborators:
Genentech, Inc.
Novartis
Treatments:
Bevacizumab
Everolimus
Sirolimus